T o facilitate their relationships with the host, certain bacteria and viruses have developed proteins that are capable of specific high avidity-binding interactions with the secreted and membrane-associated Ag receptors of B lymphocytes (BCR) 3 of the adaptive immune system (1) . Several of these Igbinding proteins have practical utility as affinity purification and detection moieties in a wide range of applications. However, the true biologic roles of these proteins remain poorly understood. Whereas these factors do not appear to be essential to the microbial life cycle, they have been assumed to be involved in the pathogenesis of infections.
Following the discovery that protein A of Staphylococcus aureus (SpA) has the capacity for specific interactions restricted to the products of defined V region gene families (2), we initiated a series of investigations that have better defined the immunobiologic properties of this prototypic Fab-binding protein. In these studies, we have characterized the molecular requirements for Fabbinding specificity of SpA (3) , and demonstrated the capacity for a high frequency of interactions with human (4) and murine B lymphocytes (5) (6) (7) (8) . In collaborative studies, we also reported the crystallographic structure of this Ig-binding protein in cocomplex with a human V H 3 Fab, which demonstrated that these interactions are mediated via BCR V region framework determinants (9) that have been highly conserved during the evolution of the immune system (7) . In parallel, we have shown that SpA can induce the in vivo deletion of V H -targeted supraclonal sets of B lymphocytes (5) , resulting in effective long-lasting immunologic tolerance to a common dominant microbial epitope important for immune defense from many infectious agents (6) . Extending these investigations, we have recently reported on our dissection of pathways by which SpA induces V H -targeted in vivo activation-induced apoptotic death of B cells (8) .
From our investigations, we have developed a structure-function model that we believe rationalizes how the capacity of SpA to induce apoptotic death of targeted B cells is directly linked to its structural organization (6, 8) . To consider whether these properties represent a paradigm common to microbial Ig-binding proteins, we have now examined the host cellular response to protein L of Peptostreptococcus magnus (PpL), a secreted membrane protein of P. magnus (also termed Finegoldia magna) (10) . This anaerobic bacterium is part of the indigenous flora of the gastrointestinal and genitourinary tracts, and the skin, although it has also been implicated in various infections (11, 12) . Bacterial virulence has been correlated with expression of PpL, which is a 76-to 106-kDa protein (13) (14) (15) composed of four or five highly homologous Fab binding domains in tandem (16) , reiterating a structural theme common to SpA. Furthermore, PpL binding has been shown to involve a framework-associated site shared by many Ig V gene products of the human immune system (17) .
To test our hypothesis, we sought to determine whether PpL, by interactions with the L chain-associated Fab binding site (18) , has the capacity to affect the B cell compartment of the adaptive immune system. In studies designed after those we have recently reported for SpA (8), we found that PpL is capable of inducing activation-associated apoptosis of B cells that are targeted via the V regions expressed in their membrane-associated BCR. Cumulatively, these findings demonstrate general principles that may also apply to the potential host interactions of microbial proteins of diverse fine Ig-binding specificities.
Materials and Methods

Mice and immunogens
T15i knockin (19) and AB29 transgenic (20) mice, which had been backcrossed to C57BL/6 background, were the kind gifts of K. Rajewsky (Harvard Medical School, Boston, MA) and H. Tighe (University of California, San Diego, CA). Other mice were obtained from The Jackson Laboratory (Bar Harbor, ME), and bred under specific pathogen-free conditions under the supervision of the University of California Animal Subjects Program. Applying a regimen previously used in studies of SpA (5-8), adult mice, at least 6 wk of age, received rPpL (TetraLink, Amherst, NY) or OVA as a control protein (Sigma-Aldrich, St. Louis, MO), from which contaminating endotoxin had been removed to a low level (Ͻ0.5 EU/ml). Unless otherwise indicated, mice received doses of 1 mg in 250 l of pyrogen-free saline, instilled into the peritoneal cavity. After sacrifice, tissues were harvested for immediate ex vivo analysis, and aliquots were also placed in culture. In studies intended to quantitate residual deletion after longer time intervals, mice received a dose of 0.4 mg of protein in saline, which was repeated after 2 and 4 days, with sacrifice 7 days after the first dose. In all experiments, mice were age and sex matched.
Flow cytometry analysis
Adapting previously reported methods (5-7), subsets of mononuclear cells were identified by staining with FITC-labeled anti-IgD (clone 11-26c.2a) or anti-CD21 (7G6), CD86 (GL-1), PE-labeled anti-CD1 (1B1), CD23 (2G8, Southern Biotechnology Associates, Birmingham, AL), CD24 (M1/ 69), CD3 (145-2C11) or CD5 (53-7.3), PerCP-labeled B220, Tricolor-labeled anti-CD19 (6D5) (Caltag Laboratories, Burlingame, CA), biotin-labeled PpL (Tetralink), anti-Ig, anti-Ig (Southern Biotechnology Associates), or isotype controls, used with streptavidin-labeled PerCP or allophycocyanin (BD PharMingen, San Diego, CA), in the presence of Fc block (BD PharMingen, San Diego, CA), as appropriate. Data were acquired using a FACSCalibur (BD Biosciences, San Diego, CA), and analyzed with FlowJo software (Treestar, Ashland, OR). Forward and side scatter gates included only nucleated viable cells; dead cells were excluded based on light scatter and 7-amino actinomycin D uptake, as possible.
To measure the activity of a proapoptotic pathway, cells were permeabilized and stained with specific affinity-purified rabbit IgG anti-activated caspase 3 (Cell Signaling Technology, Beverly, MA) and detected with PE goat anti-rabbit IgG (Southern Biotechnology Associates). Changes in mitochondrial transmembrane potential (⌬ m ) were detected by staining with JC-1 (Intergen, Purchase, NY) (21) .
Adoptive transfer studies
Isolated splenocytes were suspended at 5 ϫ 10 7 /ml in RPMI 1640, labeled with 2 M of CFSE (Molecular Probes, Eugene, OR), and incubated at 37°C for 10 min. The cells were washed three times in ice-cold RPMI 1640 with 5% FCS and resuspended in PBS. A total of 3 ϫ 10 7 splenocytes was transferred i.v. through the tail vein. After 24 h, mice received either PpL or control protein, as described above, or 500 g of the immunostimulatory CpG phosphorothioate oligonucleotide (5Ј-TGA CTG TGA ACG TTC GAG ATG A-3Ј), which was used as a positive control for proliferation (i.e., mitogen) (22) . Control studies confirmed that CFSE treatment did not compromise the ability of B cells to respond to PpL or to mitogens (data not shown).
In vitro studies
In certain studies, freshly isolated splenocytes were placed in culture at 2 ϫ 10 6 cells/ml at 37°C, 5% CO 2 in RPMI 1640 with 5% FCS, supplemented with L-glutamine, 10 mM of HEPES, amino acid solution, 1 mM of sodium pyruvate, 60 M of 2-ME, and penicillin/streptomycin.
Histology
Spleens were placed in OCT compound embedding medium (Fisher Scientific, Pittsburgh, PA) and frozen in a 2-methyl butane/dry ice bath. Sections (7 M) were cut and mounted on Superfrost Plus Slides (Fisher Scientific). Slides were fixed in 3.7% formaldehyde in PBS (pH 7.4) for 20 min at room temperature, blocked in PBS, 5% FCS for 1 h at room temperature, then stained with PE-labeled anti-B220 (diluted in blocking buffer), washed, permeabilized with 0.1% Triton X-100 in 0.1% sodium citrate for 2 min on ice, washed, and then stained with the TUNEL assay kit (Roche). After mounting with Prolong (Molecular Probes), digitized images were captured at low power (i.e., ϫ10) magnification.
Statistical analysis
Comparisons between different groups used the two-tailed Student's t test, with p values Ͻ0.05 taken as significant.
Results
PpL-binding interactions with a subset of peripheral B cells
To investigate the cellular implications for the Ig-binding activity of PpL, we first assessed for potential binding interactions with peripheral mononuclear cells from naive adult mice. As shown in Fig. 1 , we found that binding of labeled PpL was restricted to B220 ϩ mononuclear cells, and in both BALB/c and C57BL/6 mice PpL interacted with more than one-half of the B lymphocytes. Significantly, PpL binding was overwhelmingly associated with V-expressing B cells, as little or no binding by Ig-bearing B cells was detected. Moreover, although certain V-expressing B cells displayed higher PpL-binding activity, there was no distinct separation of PpL binders and nonbinders, which may indicate that -bearing B cells can display a continuous range of PpL-binding affinities. We also assessed binding in T15i knockin and AB29 transgenic mice, in which we found PpL binding was also restricted to a subset of Ig-expressing B cells, confirming that H chain usage does not directly influence PpL binding. These findings were therefore consistent with previously reported in vitro binding studies with soluble Ig (23), as we confirmed that interactions with PpL are associated predominantly (if not solely) with a subset of -bearing B cells. These results, however, were different from those in an earlier flow cytometry report that also found PpL binding by a fraction of CD19 Ϫ /CD3 ؉ mononuclear cells (24) , as presumably the B cell restriction demonstrated in our studies reflected a methodologic approach that excluded cytophilic FcR-mediated interactions.
Differential PpL binding to distinct B cell subsets
In the mouse, there are distinct sets of mature B cells believed to have specialized BCR repertoires associated with different functional roles (reviewed in Ref. 25) . To determine whether PpL binding is more commonly associated with particular B cell subpopulations, we assessed PpL binding in different anatomic compartments. In studies of adult C57BL/6 splenocytes, we applied a phenotyping strategy shown to discriminate subpopulations of mature B cells from the B cell precursors that continually emerge from the bone marrow (26) . In representative studies illustrated in Fig. 2A , we compared total surface Ig (sIg) expression on transitional bone marrow emigrants; transitional type 1 (T1) (B220 
CD1
high B cells, a set overlapping with MZ and perhaps T2 cells (27) , displayed a significantly greater representation of higher PpL binders than for B220 ϩ
low B cells, even after considering for differences in sIg levels (Fig. 2B ). These findings are consistent with the hypothesis that there is biased PpL-binding activity in different splenic mature B cell sets, with an apparent selection for PpL binders into the MZ set, and a relative paucity of PpL binders in the conventional B-2 set.
In studies of peritoneal mononuclear cells ( Fig. 2C ), we also found evidence of biased expression of PpL-binding capacity in B-1a (B220 ϩ sIgD low CD5 ϩ ) compared with both B-1b (B220 ϩ sIgD low CD5 Ϫ ) and conventional mature peritoneal B cells (i.e., B-2 cells) (B220 ϩ sIgD high CD5 Ϫ ). These correlative findings provide direct evidence that the V L repertoire of peritoneal B-1a cells can be functionally distinguished from those of local conventional B cells, which is consistent with the notion that these B cells may be responsive to, and selected by, different BCR ligands. We also examined the expression of PpL-binding activity in other peripheral lymphoid tissues. As shown in Fig. 2D , while sIg expression was relatively uniform among B cells at these different sites, we found a somewhat higher level of PpL binding in B220 ϩ cells in peripheral lymph nodes (LN) (i.e., pooled axillary and inguinal LN) compared with mesenteric LN and Peyer's patches (PP). Because at these sites there appeared to be two peaks of PpL-binding intensity, especially in the peripheral LN samples, we performed additional phenotypic characterization. These studies demonstrated that in all samples PpL binding was higher in the CD21 high CD24 high B cells, compared with the CD21 low CD24 low B cells, and these differences could not be explained based on levels of sIg expression (Fig. 2E) . Hence, these findings were also consistent with our studies of splenic B cells, in which the splenic CD21 high subsets (i.e., MZ and T2 B cells) also displayed higher levels of PpL-binding activity. These findings may reflect a distinct BCR repertoire of the CD21 high CD24 high B cell subset in LN, which in recent reports has been implicated to have special regulatory roles in the gut (28, 29) .
Modulation of membrane molecules of B cells targeted by in vivo PpL treatment
To assess how B cells may be affected by in vivo exposure, we instilled 1 mg of PpL into the peritoneal cavities of C57BL/6 mice. To identify T1 cells, we used CD21 low CD24 high B220 ϩ , which discriminates these recent B cell emigrants from other B cell types that are also CD21 low CD23 low (26, 28) . B, Splenic B cells were gated with CD1 and B220 to discriminate CD1 high B cells. C, Peritoneal B cells were gated with B220, IgD, and CD5 to discriminate B-1a, B-1b, and B-2 cells. D and E, Cells harvested from mesenteric LN (MLN), peripheral LN, and PP were analyzed as total B cells, and subdivided into CD21 high CD24 high (R1) and CD21 low CD24 low (R2) cells. The associated PpL and Ig binding of the different B cell subpopulations is illustrated in adjacent histograms with mean fluorescence intensity depicted in a corresponding color. Results depicted are from representative studies of adult C57BL/6 mice.
As shown in Fig. 3A , when examined 16 h after in vivo PpL treatment, a subset of -bearing splenic (B220 ϩ ) (top, right) displayed significantly down-regulated sIg, while Ig-bearing B cells were not affected (bottom, right), compared with mice that were instead treated with a control protein (at left). We also found that PpL treatment resulted in a transient increase in the representation of Ig-bearing B cells in the spleen (data not shown), which most likely represents an induced early trafficking of affected B cells into the spleen akin to that documented after SpA treatment (8) .
We found that PpL treatment also induced affected Ig-bearing B cells to up-regulate CD86, an early marker of cellular activation (Fig. 3B) . By contrast, PpL treatment did not affect CD86 expression on Ig-bearing B cells. In other studies, we confirmed that this induced activation phenotype was restricted to the B cells with down-regulated V-associated sIg.
In vivo clonal fate after PpL treatment
We next evaluated whether PpL treatment altered the clonal fate of the targeted B cells. For these studies, C57BL/6 splenocytes were labeled with CFSE and then adoptively transferred into C57BL/6 recipients. At 48 h after treatment, the spleens of treated recipient mice were harvested and evaluated. In a representative study shown in Fig. 4 , treatment with the B cell-specific mitogen, CpG DNA (a positive control), was shown to induce proliferation in ϳ40% of labeled B cells. However, in these mice, there were no significant differences in the responses of sIg-bearing B cells (or the subset of B cells detected based on PpL-binding capacity) or Ig-bearing B cells (data not shown), which confirmed that there was no BCR selectivity in the response to this mitogen. By contrast, following PpL treatment, we found that a smaller proportion (ϳ5.5%, p Ͻ 0.002) of Ig-bearing B cells had undergone one or two rounds of proliferation, but this was still greater than the low background levels detected in control protein-treated mice. Importantly, in analysis focused on PpL-binding B cells, a significantly larger proportion (ϳ9%, p Ͻ 0.0006) of these targeted B cells was found to have undergone proliferation. These levels of induced proliferation for Ig-and PpL-binding B cells were also much higher than those detected for Ig-bearing B cells (data not shown), although the small number of sIg-bearing B cell events detected in our flow cytometric studies made quantitation less meaningful.
PpL treatment induces supraclonal deletion of a subset of V-bearing splenic B cells
In our studies of transferred CFSE-labeled splenocytes, we also evaluated whether PpL treatment results in detectable changes in the subsequent representation of mature B cells at 48 h after treatment. Applying previously described methods (8), we looked for altered representation based on B-T cell ratios. In the spleens of the mitogen-treated mice, we found a mean 296 Ϯ 18% increase of labeled B cells, which was consistent with the above-described evidence of massive proliferation. Significantly, despite the limited proliferation that followed PpL treatment, there was still a 34 Ϯ 7.5% (mean Ϯ SD) overall decrease of labeled splenic B cells in the PpL-treated mice compared with the control-treated mice ( p Ͻ 0.004) (from groups of four mice pooled from two independent experiments). Notably, we also evaluated the outcome at 72 h after treatment, and although we found that a limited number of B cells had now undergone three rounds of proliferation, the same net levels of B cell deletion were still documented (data not shown). These studies document that even though PpL can induce proliferation detectable in a small subset of surviving Ig-bearing B cells, this limited supraclonal expansion was insufficient to replace the larger number of B cells targeted for in vivo deletion. Moreover, these findings are different from those for a model T cell superantigen, which was reported to initially induce a supraclonal expansion due to a discrete number of divisions before supraclonal deletion resulted (8) .
We also determined the clonal outcome in mice that received a more intensive treatment regimen, which enabled evaluations at a later time point when death-inducing events should have been completed. For these studies, C57BL/6 mice received three doses of PpL (or control protein) and were then evaluated 7 days after the initial treatment. Consistent with the prediction that by this time point there should also have been normalization of any induced phenotypic changes on surviving B cells, we found that PpL treatments did not result in an increased representation of Ig-negative B cells in the spleen (data not shown). In results pooled from two independent experiments, we found that PpL treatment resulted in a significant loss (mean 34 Ϯ 6%, p ϭ 0.003 for groups of four mice) of splenic B cell (i.e., B220 ϩ ) compared with control-treated mice. Moreover, while in control-treated mice 87 Ϯ 3.2% of B cells had surface Ig, PpL treatment resulted in a significant decrease in the representation of Ig-bearing B cells to 76 Ϯ 3.2% ( p Ͻ 0.01) (Fig. 5) . The inverse pattern was demonstrated for the representation of Ig-bearing B cells, as in the control-treated mouse 13 Ϯ 0.8% of splenic B cells displayed sIg, while PpL treatment significantly increased the representation of sIg-bearing B cells to ϳ21% ( p Ͻ 0.0006). These findings are especially important, as Ig-bearing B cells are not directly affected by PpL treatment; hence, this apparent increase in Ig-bearing B cell representation must be a reflection of the contraction of the Ig-bearing B cell population.
Deletion reflects apoptotic death
Based on our experience with mice treated with SpA, we wondered whether the PpL-induced loss of B cells represented supraclonal deletion due to the induction of an apoptotic pathway, so we looked for evidence of induced mitochondrial membrane permeabilization that reflects the early phase of the intrinsic apoptosis pathway. As shown in Fig. 6 , akin to our recently reported findings in SpA-treated mice, compared with control-treated mice we found limited changes in mitochondrial membrane changes (⌬ m ) in a subset of B cells as early as 4 h after PpL treatment (data not shown), and even greater changes in ⌬ m of B cells were readily detected 48 h after PpL treatment, while T cells (i.e., CD3 ϩ ) in the same samples were unaffected.
We also looked for evidence of induction of the caspase pathway, which are cysteine proteases that often play a central role in apoptotic death pathways. In several studies, at 16 h after in vivo exposure, splenocytes were harvested and placed in culture without additional stimulants. After 24 h in culture, we found that B cells from PpL-treated mice displayed progressive increases in the level of intracellular activated caspase 3 (Fig. 7A) . As activation of caspase 3 represents an essentially irreversible final common pathway of apoptosis, these findings indicate that PpL treatment commits targeted B cells to apoptotic death.
To verify that these findings accurately reflect the apoptotic pathway of in vivo death in V L -targeted B cells, we also performed immunohistochemical analyses that looked for induction of cellular DNA fragmentation in targeted B cells using the TUNEL assay, which detects DNA 3Ј-hydroxyl ends resulting from caspase-activated DNA cleavage (30, 31) . As shown in Fig. 7B , we compared the spleens of control protein-treated mice with those that had received either SpA or PpL treatment. At 48 h after treatment, we found that both SpA treatment and PpL treatment resulted in the increased in situ deposition of B220 ؉ TUNEL-positive apoptotic bodies in B zones of primary follicles, and which appeared to be excluded from the T zones (Fig. 7B) . In control-treated mice, only a low background level of B cell apoptotic bodies was detected, while a significantly higher level of B cell apoptotic bodies was detected after SpA treatment ( p ϭ 0.004) (Fig. 7C) . Importantly, compared with the control-treated mice, a much higher level of apoptotic bodies was also detected after PpL treatment ( p Ͻ 0.0001). In fact, we were impressed to find that the representation of B cell apoptotic bodies was significantly higher in the PpLtreated than in the SpA-treated mice ( p ϭ 0.0008). These frequencies of induced apoptotic B cells also appeared to be roughly proportional to the frequency of B cells in naive adult mice that are capable of Fab-mediated SpA-binding activity (i.e., 5-10%) (5, 6) and PpL-binding activity (ϳ55%) (Fig. 1) , as detected by flow cytometry. Taken together, these studies document that PpL treatment induces the V-targeted in vivo apoptotic death of B cells in peripheral lymphoid tissues.
Discussion
In the current studies, we have demonstrated that PpL, a secreted membrane protein of a common anaerobic isolate of clinical infections, can induce V L -targeted BCR-mediated in vivo apoptotic death. In murine strains with polyclonal B cell repertoires, PpL elicited a sequence of events initiated by sIg down-regulation and increased expression of activation-associated surface phenotypic markers. This was followed by progression of a death pathway involving alterations in mitochondrial membrane potential that led to apoptosis. In fact, the induction of in vivo apoptotic death was rigorously documented by the finding of in situ deposition of 
B220
ϩ apoptotic bodies, demonstrated by the TUNEL assays, in primary follicles in the peripheral lymphoid organs (Fig. 7) .
These studies support our fundamental hypothesis that, despite completely distinct fine binding specificities within the Fab portion of the BCR, protein L can induce a supraclonal B cell fate, which is the same as we have recently shown following in vivo exposure to SpA (8). Before we performed these studies, the only available reports on the cellular interactions of PpL had been limited to binding studies on naive mononuclear cells (24) , and in vitro assays demonstrating that PpL (like SpA) is capable of triggering mast cells and basophils via their membrane-bound Ig (32) . In fact, we were uncertain whether PpL was capable of deleting B cells, as we were concerned that PpL might not induce a suitable BCR signal due to subtle differences in affinity or avidity, or perhaps because affected B cells might have the potential capacity to recruit additional second signals. We were gratified to determine that using similar in vivo doses, while SpA was shown to induce deletion of mean 68% of Ig transgene-expressing susceptible splenic B cells (8) , PpL induced a mean 44% loss of polyclonal Ig-expressing splenic B cells. Moreover, the frequencies of the deposition of B cell apoptotic bodies in the spleen (Fig. 7) were also proportional to the representation of polyclonal B cells capable of these binding interactions, as detected by flow cytometry. Admittedly, although in our studies the most apparent overall induced lymphocyte fate was apoptotic death, minor sets of B lymphocytes may well have been induced to undergo alternate fates, which may include functional inactivation (i.e., anergy), supraclonal expansion, or enddifferentiation, possibly due to variations in their intrinsic binding affinities for protein L, or other factors. In particular, it remains potentially possible that certain B cells responding to PpL may escape through receptor editing (33, 34) or by receptor dilution (35) , mechanisms that may be more commonly linked to L chainthan to H chain-targeted interactions.
Our results document similar potencies of two unrelated microbial proteins to induce BCR-mediated effects on B cells, despite the fact that these proteins target distinct conserved sites on host B cell Ag receptors. These proteins also embody two very different structural approaches to convey similar functional capacities. An Ig-binding domain of SpA uses side chains ␣ helices 2 and 3 to compose a V H 3 Fab binding site, which is separate and functionally independent (9) from the binding site for Ig Fc␥ that involves helix 1 and 2 (as originally described by Deisenhofer (36) ). By contrast, in a recent report, Graille et al. (18) also showed that one 61-residue polypeptide domain derived from PpL contains a V binding site that is formed by two pairs of antiparallel ␤ strands and a helix that lies on top of the sheet. Although much less is known about the interactions of PpL compared with SpA, these authors suggested that a single domain of PpL may actually have two separate Ig binding sites of the same, or similar, binding specificities (37) .
Although SpA is exquisitely specific for the products of structurally and genetically related homologous genes within the V H 3 clan, the genetic and structural relationships of V genes within and between species are less well defined. Moreover, it is also currently unclear whether this alternate structural strategy of PpL provides a similar restriction, or greater promiscuity, for potential BCR-binding interactions. Nonetheless, the current studies dramatically demonstrate the functional equivalence of PpL-binding interactions that may affect one-half or more of V-expressing B cells in both BALB/c and C57BL/6 mice. The V binding site of PpL and the V H binding site of SpA both convey one-point binding interactions with Fab in the M range, and binding is greatly enhanced by the avidity inherent to the four or more domains present in each of these native proteins (18, 38, 39) . We hypothesize that these structural features impart the capacity to target specific B cells for superantigen-mediated lymphocyte deletion. These insights also suggest that these two different Fab-binding proteins arose by convergent evolution to convey very similar immunobiologic activities. Although our findings document a V region-targeted B cell apoptotic deletion, interactions of PpL (or SpA) with non-B cells may still provide in vivo cofactors that contribute to the B cell deletion process.
Although actual sequence data are limited, reported studies have shown that PpL has the capacity for binding interactions with isolated Ig L chains from the human V1, 3, and 4 gene families. However, it is unknown whether these interactions are common to all Ig products derived from these families, and binding to some L chains has also been reported (40) . Significantly, the Ig products of these particular V gene families share similar key residues, which include first framework subdomain residues implicated as contact sites in the reported PpL-Fab cocrystal (18) . However, rigorous examinations of the requirements and limitations for these interactions have not been reported. In preliminary studies, we have identified murine monoclonal Ig of known V region sequences, which display PpL-binding capacity (our manuscript in preparation). These functional observations are consistent with genetic and sequence correlations reported by Zachau and coworkers (41) , as our data suggest that murine analogues of human V1, 3, and 4 families may also commonly convey PpL-binding activity. However, these comparative studies are complicated by the fact that, whereas humans have 7 human V families (of which only 4 are commonly expressed) (42) , the mouse expresses 18 distinct V families that embody much greater genetic and structural diversification, and ϳ30% of potentially functional murine genes have uncertain or unknown human analogues (41) . In any case, the current findings contribute to the notion that diverse mammalian species (i.e., human and mouse), separated by many million years of evolution, have adaptive immune systems that have conserved highly expressed V H and V binding sites for microbial products of common colonizing/pathogenic microbes.
We were also intrigued to discover that the representation of murine B cells that can bind, and presumably can be modulated by PpL, varies in distinct B cell subsets at different sites in the body. Among mature B cell populations, there was a much greater representation of strong PpL binders among B-1a cells, with somewhat lower level among MZ B cells and splenic CD1 high B cells, while strong binders were much less common among conventional recirculating follicular B cells. Although the maturational relationship between these B cells and precursors from the central compartment is still controversial, we found circumstantial evidence suggesting great relative enrichment of PpL binders among T2 cells, compared with the T1 cells from which they derive. One interpretation is that from newly emergent B cells, there is also a selection bias for PpL binders into the MZ and B-1 pools, while there is a concurrent selection against PpL binders into the pool of B-2 cells, which may later be recruited into germinal center responses to protein Ags. In addition, we were intrigued to find B cell sets with differential PpL-binding activity in LN and PP. Our results indicate that CD21
high B cells at these sites have a V repertoire with the same increased representation of PpL binders as found in splenic CD21 high B cells (i.e., T2 and MZ), representing a bias compared with other B cells. In earlier studies, splenic CD21 high cells have been shown to be more susceptible to in vitro BCR-mediated death (43), and we have recently shown they also have increased susceptibility to SpA-induced BCR death (manuscript in preparation). We wonder whether the roles that CD21 high B cells play in the defense from infection also make them attractive targets for the development of microbial virulence factors.
In a limited survey of clinical isolates, PpL expression was associated with only 10 -15% of P. magnus isolates, but PpL production appeared to correlate with virulence (14) . Although a role in pathogenesis is uncertain, Bjorck and colleagues (14) recently described an innovative murine model of infection in which the introduction into Streptococcus gordonii of PpL expression facilitated murine vaginal colonization and clinical features akin to those of P. magnus-associated vaginosis. These studies, however, did not experimentally address the mechanistic basis for this altered host-pathogen relationship. Although enhanced adhesion capacity was discussed, evidence that PpL can be a secreted microbial factor during colonization/infection is consistent with the notion that PpL may affect large sets of host B lymphocytes, potentially by acting either locally or systemically. It should be appreciated that in the current studies, while PpL doses were administered into the peritoneal cavity, dramatic effects were demonstrated in lymphocytes at remote anatomic sites. Moreover, as ϳ40% of circulating murine Ig are capable of PpL-binding interactions (44), our findings document that soluble PpL can travel through the bloodstream, unhindered by the great molar excesses of circulating Ig, to induce altered B cell clonal fates at distant sites in the immune system.
We wonder whether the B cell modulatory properties of PpL can play a role in infection. From our surveys, it is likely that B cells enriched in BCR-mediated PpL-binding activity may normally be important in the defense from bacterial invasion. To explain these findings, we wonder whether the specificity of PpL was shaped by the goal of pre-emptive inactivation of B cell defenders of mucosal surfaces. It may therefore not be a coincidence that B cells targeted by PpL are especially enriched in B cell populations that are specific for nonprotein bacterial Ags (i.e., MZ and B-1a cells). In future investigations, it may therefore be important to examine whether infections by microbes that produce Ig-binding proteins are especially effective at perturbing B cell function and clonal regulation at sites directly adjacent to (or remote from) sites of infections.
